Form 4: Crinetics Pharmaceuticals CFO Marc Wilson Executes Stock Option and Sells Shares
SEC Form 4 Filing
CFO Marc Wilson exercised stock options and sold shares of Crinetics Pharmaceuticals on June 28, 2024, according to a recent SEC filing.
Summary
- On June 28, 2024, Marc Wilson, CFO of Crinetics Pharmaceuticals, exercised stock options to acquire 32,129 shares of common stock at a price of $9.28 per share.
- Simultaneously, Wilson sold 32,129 shares of common stock in the open market at a volume weighted average price of $43.61 per share.
- Following these transactions, Wilson directly owns 111,092 shares of Crinetics Pharmaceuticals common stock.
- Wilson also holds options to purchase 19,056 shares.
- The sale was executed automatically pursuant to a Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The fact that the sale was pre-planned under a 10b5-1 plan reduces the likelihood of a strong negative reaction.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard transaction unless the volume is unusually high or low compared to historical insider trading patterns at Crinetics.
Key Dates
| Date | Description |
|---|---|
| 06/25/2018 | 1/48th of the shares subject to the option vested on this date, with subsequent monthly vesting. |
| 05/24/2028 | Expiration date of the stock options. |
| 06/28/2024 | Date of the stock option exercise and share sale. |
| 07/02/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.